Metastatic Urothelial Cancer

DrugDrug NameDrug Description
DB13007Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
DrugDrug NamePhaseStatusCount
DB13007Enfortumab vedotin1Completed1
DB09037Pembrolizumab1Completed1
DB11945Avelumab2Active Not Recruiting1
DB00958Carboplatin2Active Not Recruiting1
DB00958Carboplatin2Recruiting1
DB00441Gemcitabine2Active Not Recruiting1
DB00441Gemcitabine2Recruiting1
DB09035Nivolumab2Recruiting1
DB09074Olaparib2Recruiting1
DB00526Oxaliplatin2Recruiting1
DB01229Paclitaxel2Recruiting1
DB15766Retifanlimab2Active Not Recruiting1
DB00958Carboplatin2 / 3Completed1
DB00515Cisplatin2 / 3Completed1
DB00441Gemcitabine2 / 3Completed1
DB00958Carboplatin3Recruiting1
DB00515Cisplatin3Recruiting1
DB11714Durvalumab3Recruiting1
DB00441Gemcitabine3Recruiting1
DB11771Tremelimumab3Recruiting1